Sufyan Hussain, Asli Zeynep Ozdemir Saltik, Jessica J Yu, Simona de Portu, Richard F Pollock, Johannes Pöhlmann, Ohad Cohen
{"title":"改善1型糖尿病的时间范围:预测自动化胰岛素输送的临床和成本影响。","authors":"Sufyan Hussain, Asli Zeynep Ozdemir Saltik, Jessica J Yu, Simona de Portu, Richard F Pollock, Johannes Pöhlmann, Ohad Cohen","doi":"10.1177/15209156251380593","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Introduction:</i></b> Time in range (TIR) has emerged as a key target in managing people with type 1 diabetes (PwT1D). The time spent in a glucose range of 70-180 mg/dL (3.9-10.0 mmol/L; TIR) is recommended to be >70%, which has been linked to reduced complication incidence. While frequently used in evaluating automated insulin delivery, TIR has rarely been applied in health economic assessments. This analysis therefore examined the impact of a 10-percentage point increase in TIR on clinical and economic outcomes for PwT1D. <b><i>Methods:</i></b> Four baseline TIR levels (50%, 60%, 70%, 80%) and the investigated TIR increase were mapped to glycated hemoglobin (HbA1c) using two published statistical approaches. HbA1c estimates informed the IQVIA CORE Diabetes Model, projecting cumulative complication incidence, life expectancy, quality-adjusted life expectancy (QALE), and costs over 20 years from an English public health care system perspective. Cohort baseline data, complication costs, and utilities were sourced from an economic assessment by the National Institute for Health and Care Excellence. Sensitivity analyses were performed to assess the robustness of results. <b><i>Results:</i></b> A 10-percentage point TIR increase reduced the cumulative incidence of complications, by 15.6%-53.0%, 8.8%-47.1%, 8.1%-33.5%, and 10.1%-17.6% for ophthalmic, renal, neuropathic, and cardiovascular complications, respectively, when averaged across baseline TIR levels. Fewer complications translated into life expectancy gains of 0.031-0.051 years and QALE gains of 0.056-0.143 quality-adjusted life-years, with higher gains for lower baseline TIR. Total projected cost reductions versus constant TIR were 7.5%-9.9%, driven by reduced complication costs. <b><i>Conclusions:</i></b> Long-term projections for England suggested that a 10-percentage point increase in TIR reduced diabetic complications in PwT1D, thereby reducing spending on complication treatment. Improvements were seen across baseline TIR levels but were disproportionately accrued in those with lower baseline TIR.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":""},"PeriodicalIF":6.3000,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Improving Time-in-Range in Type 1 Diabetes: Projecting the Clinical and Cost Implications of Automated Insulin Delivery.\",\"authors\":\"Sufyan Hussain, Asli Zeynep Ozdemir Saltik, Jessica J Yu, Simona de Portu, Richard F Pollock, Johannes Pöhlmann, Ohad Cohen\",\"doi\":\"10.1177/15209156251380593\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b><i>Introduction:</i></b> Time in range (TIR) has emerged as a key target in managing people with type 1 diabetes (PwT1D). The time spent in a glucose range of 70-180 mg/dL (3.9-10.0 mmol/L; TIR) is recommended to be >70%, which has been linked to reduced complication incidence. While frequently used in evaluating automated insulin delivery, TIR has rarely been applied in health economic assessments. This analysis therefore examined the impact of a 10-percentage point increase in TIR on clinical and economic outcomes for PwT1D. <b><i>Methods:</i></b> Four baseline TIR levels (50%, 60%, 70%, 80%) and the investigated TIR increase were mapped to glycated hemoglobin (HbA1c) using two published statistical approaches. HbA1c estimates informed the IQVIA CORE Diabetes Model, projecting cumulative complication incidence, life expectancy, quality-adjusted life expectancy (QALE), and costs over 20 years from an English public health care system perspective. Cohort baseline data, complication costs, and utilities were sourced from an economic assessment by the National Institute for Health and Care Excellence. Sensitivity analyses were performed to assess the robustness of results. <b><i>Results:</i></b> A 10-percentage point TIR increase reduced the cumulative incidence of complications, by 15.6%-53.0%, 8.8%-47.1%, 8.1%-33.5%, and 10.1%-17.6% for ophthalmic, renal, neuropathic, and cardiovascular complications, respectively, when averaged across baseline TIR levels. Fewer complications translated into life expectancy gains of 0.031-0.051 years and QALE gains of 0.056-0.143 quality-adjusted life-years, with higher gains for lower baseline TIR. Total projected cost reductions versus constant TIR were 7.5%-9.9%, driven by reduced complication costs. <b><i>Conclusions:</i></b> Long-term projections for England suggested that a 10-percentage point increase in TIR reduced diabetic complications in PwT1D, thereby reducing spending on complication treatment. Improvements were seen across baseline TIR levels but were disproportionately accrued in those with lower baseline TIR.</p>\",\"PeriodicalId\":11159,\"journal\":{\"name\":\"Diabetes technology & therapeutics\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":6.3000,\"publicationDate\":\"2025-09-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes technology & therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/15209156251380593\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes technology & therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/15209156251380593","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
摘要
范围内时间(Time in range, TIR)已成为管理1型糖尿病(PwT1D)患者的关键指标。血糖维持在70-180 mg/dL (3.9-10.0 mmol/L; TIR)范围内的时间建议为70%,这与减少并发症发生率有关。虽然TIR经常用于评估自动胰岛素输送,但很少用于卫生经济评估。因此,该分析检查了TIR增加10个百分点对PwT1D临床和经济结果的影响。方法:采用两种已发表的统计方法,将4个基线TIR水平(50%、60%、70%、80%)和所研究的TIR升高与糖化血红蛋白(HbA1c)相关联。从英国公共卫生保健系统的角度来看,HbA1c估计为IQVIA CORE糖尿病模型提供了信息,预测了累积并发症发生率、预期寿命、质量调整预期寿命(QALE)和20年以上的成本。队列基线数据、并发症成本和效用来源于国家健康与护理卓越研究所的经济评估。进行敏感性分析以评估结果的稳健性。结果:当基线TIR水平平均时,10个百分点的TIR增加可使眼部、肾脏、神经病变和心血管并发症的累积发生率分别降低15.6%-53.0%、8.8%-47.1%、8.1%-33.5%和10.1%-17.6%。更少的并发症转化为0.031-0.051年的预期寿命增加和0.056-0.143年的质量调整生命年增加,基线TIR越低,收益越高。与固定TIR相比,由于并发症成本降低,预计总成本降低7.5%-9.9%。结论:英国的长期预测表明,TIR增加10个百分点可减少PwT1D的糖尿病并发症,从而减少并发症治疗的支出。基线TIR水平均有改善,但在基线TIR较低的患者中,改善程度不成比例。
Improving Time-in-Range in Type 1 Diabetes: Projecting the Clinical and Cost Implications of Automated Insulin Delivery.
Introduction: Time in range (TIR) has emerged as a key target in managing people with type 1 diabetes (PwT1D). The time spent in a glucose range of 70-180 mg/dL (3.9-10.0 mmol/L; TIR) is recommended to be >70%, which has been linked to reduced complication incidence. While frequently used in evaluating automated insulin delivery, TIR has rarely been applied in health economic assessments. This analysis therefore examined the impact of a 10-percentage point increase in TIR on clinical and economic outcomes for PwT1D. Methods: Four baseline TIR levels (50%, 60%, 70%, 80%) and the investigated TIR increase were mapped to glycated hemoglobin (HbA1c) using two published statistical approaches. HbA1c estimates informed the IQVIA CORE Diabetes Model, projecting cumulative complication incidence, life expectancy, quality-adjusted life expectancy (QALE), and costs over 20 years from an English public health care system perspective. Cohort baseline data, complication costs, and utilities were sourced from an economic assessment by the National Institute for Health and Care Excellence. Sensitivity analyses were performed to assess the robustness of results. Results: A 10-percentage point TIR increase reduced the cumulative incidence of complications, by 15.6%-53.0%, 8.8%-47.1%, 8.1%-33.5%, and 10.1%-17.6% for ophthalmic, renal, neuropathic, and cardiovascular complications, respectively, when averaged across baseline TIR levels. Fewer complications translated into life expectancy gains of 0.031-0.051 years and QALE gains of 0.056-0.143 quality-adjusted life-years, with higher gains for lower baseline TIR. Total projected cost reductions versus constant TIR were 7.5%-9.9%, driven by reduced complication costs. Conclusions: Long-term projections for England suggested that a 10-percentage point increase in TIR reduced diabetic complications in PwT1D, thereby reducing spending on complication treatment. Improvements were seen across baseline TIR levels but were disproportionately accrued in those with lower baseline TIR.
期刊介绍:
Diabetes Technology & Therapeutics is the only peer-reviewed journal providing healthcare professionals with information on new devices, drugs, drug delivery systems, and software for managing patients with diabetes. This leading international journal delivers practical information and comprehensive coverage of cutting-edge technologies and therapeutics in the field, and each issue highlights new pharmacological and device developments to optimize patient care.